Artificial Intelligence-Enhanced Electrocardiogram
Artificial intelligence-enhanced electrocardiogram has emerged as an effective tool for the detection and prognostication of cardiac amyloidosis. In this series, we present 4 cases that demonstrate the potential of the artificial intelligence-enhanced electrocardiogram as a useful tool for monitoring treatment response in cardiac amyloidosis.
Authors
- Angela A. Dispenzieri (ORCID: https://orcid.org/0000-0001-8780-9512)
- Rafaël Fonseca (ORCID: https://orcid.org/0000-0002-5938-3769)
- Reid P Schlesinger (ORCID: https://orcid.org/0009-0006-9340-5761)
- David Harmon (ORCID: https://orcid.org/0000-0002-8102-3380)
- Iuri Ferreira Félix (ORCID: https://orcid.org/0000-0002-9613-2563)
- Awais Amjad Malik (ORCID: https://orcid.org/0000-0001-6135-4636)
- Martha Grogan (ORCID: https://orcid.org/0000-0002-2541-4440)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.jaccas.2024.102968
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Alnylam Pharmaceuticals
- Celgene
- Prothena
- National Institutes of Health
- National Cancer Institute